| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Malin Life Sciences Holdings Ltd | 10%+ Owner | $63.3M | Aug 8, 2022 | ||
| Eric Ostertag | Director | $9.57M | Feb 1, 2023 | ||
| Kristin Yarema | President and CEO, Director | $3.25M | Jan 2, 2024 | ||
| Mark J. Gergen | Executive Chairman, Director | $2.69M | Mar 1, 2024 | ||
| Brent Warner | President, Gene Therapy | $1.73M | Mar 1, 2024 | ||
| Johanna Mylet | Chief Financial Officer | $1.02M | Mar 1, 2024 | ||
| Harry J. Leonhardt | GC & Chief Compliance Officer | $886K | Mar 1, 2024 | ||
| Syed Ali-aamir Rizvi | Chief Medical Officer | $764K | Apr 1, 2024 | ||
| Matthew A. Spear | Chief Medical Officer | $596K | Mar 1, 2022 | ||
| Charles M. Baum | Director | $325K | Jun 17, 2024 | ||
| Kerry D. Ingalls | Chief Operating Officer | $294K | Mar 16, 2022 | ||
| Marcea Bland Lloyd | Director | $285K | Jun 17, 2024 | ||
| Luke Corning | Director | $243K | Jun 17, 2024 | ||
| John P. Schmid | Director | $243K | Jun 17, 2024 | ||
| Rafael Amado | Director | $243K | Jun 17, 2024 | ||
| Cynthia Collins | Director | $243K | Jun 17, 2024 | ||
| David Hirsch | Director | Jul 23, 2021 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|